VIDEO: Felicia Hill-Briggs, PhD, Addresses Quality of Life and Adherence Outcomes in Clinical Trials

In this video, Felicia Hill-Briggs, PhD, discusses how adherence and quality-of-life outcomes are equally important in overall treatment effectiveness data for clinical trials, as it is important to distinguish whether negative treatment effectiveness data are indicative of the performance of the drug itself or poor adherence by the participant. In addition, it’s important to track medication adherence during clinical trials, so that these data can be considered as part of the treatment’s overall effectiveness or ineffectiveness during the review process.

Dr. Hill-Briggs also notes that quality-of-life data are important because it determines whether a patient will continue or maintain a treatment. “Patients have to manage their diseases and medical conditions, particularly diabetes, in the context of living a life and for a lifetime,” says Dr. Hill-Briggs.